Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by biorunon Jan 06, 2022 1:42pm
125 Views
Post# 34289888

RE:RE:RE:RE:Helpful insights

RE:RE:RE:RE:Helpful insights

Thank you Tickle. Well said, and you accurately highlight the difference in perspectives, and I am ok with your views, when you are rational. You are here as I understand to get some real gains out of that original decision to buy shares. Well guess what, we share that in common.

I have done my due diligence on Pullan, and while we should all be careful due to the past, she and her team brings up the calibre of representation here for us long term, sometimes very frustrated shareholders. I admit I have been extremely frustrated in the past, but I do acknowledge that when Sirona brings on such talent, and that talent has credibility in supporting so many companies get to the finish line, and at the right time when they are going into negotiations, that also means this person can work with a wide range of leaders and perspectives.

I also think there is animal health and anti-viral (to partner on clinical trial) on the nearer term radar, if they can get a quality deal done on any of these three, then the other two will be easier to get through as well. The anti-viral is subject to Geraldine's science and the animal health is subject to the re-engagement of those parties post merger.

Lets hope to celebrate at the Finish Line.
 

<< Previous
Bullboard Posts
Next >>